LuNGS Alliance, an initiative led by the Cancer Research and Statistic Foundation (CRSF), has announced free Lung NGS (Next Generation Sequencing) biomarker testing for lung cancer patients across India. This initiative is backed by AstraZeneca, Pfizer, and Roche, with 4baseCare serving as the official lab partner. The initiative aims to drive awareness about precision oncology as an essential, accessible and affordable treatment plan for lung cancer treatment.
The TARGT First Solid test by 4baseCare offers a comprehensive analysis of 72 commonly mutated genes, identifying actionable biomarkers that enable personalized treatment plans based on a patient’s unique genomic profile. The test identifies mutations corresponding to therapies approved by the FDA and NCCN (National Comprehensive Cancer Network), empowering oncologists to provide tailored, more effective treatments that can significantly improve patient outcomes. The primary goal of this initiative is to bridge the gap between innovative cancer care and its accessibility. By offering zero-cost biomarker testing, LuNGS Alliance aims to ensure that financial constraints do not prevent patients from receiving advanced cancer treatment.
According to a study published in The Lancet Regional Health, lung cancer accounts for an estimated 72,510 new cases and 66,279 deaths annually in India. The high mortality rate highlights the urgent need for personalised treatment approaches over the conventional one-size-fits-all methods. Biomarker testing addresses this challenge by offering targeted therapies based on a patient’s unique genetic mutations.
Dr Kumar Prabhash from Cancer Research and Statistic Foundation said, “We are committed to ensuring lung cancer patients in India have access to effective, targeted treatments. With precision oncology, we aim to make life-saving innovations accessible and transform cancer care nationwide.”
Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “Advanced NGS-based biomarker testing should be standard for every lung cancer patient. This initiative brings us closer to democratising precision medicine and making a real difference in patients’ lives.”
